Topical treatment of genital warts in men, an open study of podophyllotoxin cream compared with solution.
OBJECTIVE
To evaluate the clinical efficacy of a 0.15% and a 0.3% cream formulation of podophyllotoxin in comparison with the 0.5% solution in the treatment of condylomata acuminata and to compare the treatment modalities regarding side effects.


METHODS
The study was designed as an open randomised trial. Ninety male patients with signs of penile HPV infection, with either acuminate or papular lesions, were randomised into three parallel treatment groups. The study medication comprised 0.15% and 0.3% cream and 0.5% solution of podophyllotoxin. The patients treated themselves twice daily for three consecutive days and if total regression of the warts was not achieved after this first treatment cycle, further treatment cycles at 7-day intervals were to be repeated up to a maximum of four treatments.


METHODS
The study was carried out in three outpatient clinics: two STD clinics, Department of Dermatology and Venereology, University Hospital (45 patients) and Institut Antoine Fournier, Paris (30 patients), and one military hospital, S1/FO 47/48, Sjukhusenheten, Enköping (15 patients).


RESULTS
Statistical evaluation of the treatment effect was based on a "Response rate" calculation at each visit. The number of completely responding patients after the first, second, third and fourth cycle were 40 (44%), 61 (68%), 67 (74%) and 70 (78%), respectively. There was no statistically significant difference between the three treatments after four treatment cycles. However, the 0.15% cream had a significantly slower onset of efficacy as compared with the 0.3% cream and 0.5% solution. Adverse effects were less severe and less frequent with the 0.15% cream than with the other treatment modalities. Severe adverse effects were reported by 12 patients, of whom two were treated with 0.15% cream, five with 0.3% cream and five with 0.5% solution. Thirty-one patients were completely free from adverse effects.


CONCLUSIONS
In this open randomised study with three parallel treatment groups, two cream formulations of 0.15% and 0.3% podophyllotoxin and a 0.5% solution of the same drug all showed an equally good response rate after four treatment cycles. Reported adverse effects were few and mild. The convenience of having different formulations to offer when prescribing treatment for condylomata must be considered.
Strand
A
A
Department of Dermatology and Venereology, University Hospital, Uppsala, Sweden.
Brinkeborn
R M
RM
Siboulet
A
A
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D003218:Condylomata Acuminata / Q000188:drug therapy*; D003875:Drug Eruptions / Q000209:etiology; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009824:Ointments; D010409:Penile Diseases / Q000188:drug therapy* / Q000821:virology; D011034:Podophyllotoxin / Q000008:administration & dosage* / Q000009:adverse effects; D011537:Pruritus / Q000139:chemically induced; D016896:Treatment Outcome
D007641:Keratolytic Agents; D009824:Ointments; D011034:Podophyllotoxin